Global Erectile Dysfunction Drugs Market By Drug Type (Viagra, Cialis, Stendra/Spedra, Zydena, Levitra/Staxyn, Vitaros, and, Other Drugs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends, and Forecast 2023-2032

Report Overview

Global Erectile Dysfunction Drugs Market size is expected to be worth around USD 6.2 Billion by 2032 from USD 3.2 Billion in 2022, growing at a CAGR of 6.8% during the forecast period from 2023 to 2032.

Erectile dysfunction is the inability to achieve or maintain a firm enough penile erection during intercourse. Erectile dysfunction is the most common sexual disorder among males.

In addition, stress can cause it to affect the patient’s physical and mental health. Two leading causes of erectile dysfunction are physiological factors such as high blood pressure and high cholesterol, obesity, tobacco use, or smoking, as well as psychological causes like stress, mental health issues, and depression.

Therefore, market growth is driven by rising disease prevalence and increased demand for (ED) erectile dysfunction medications.

*Actual Numbers Might Vary In The Final Report

Key Takeaways

• The Erectile Dysfunction Drugs Market is expected to reach USD 6.1 billion by 2032.
• The ED Drugs market was valued at USD 3.2 billion in 2022.
• The market is expected to grow at a CAGR of 6.8% from 2022 to 2032.
• Viagra (Sildenafil Citrate) holds a 58% revenue share in the erectile dysfunction drugs market.
• Viagra typically costs between USD 70 to 75 per pill.
• Retail pharmacies hold the largest revenue share at 46% in the distribution channel.
• North America had the highest revenue share in the market in 2022 at 51.7%.
• Asia Pacific’s revenue share in 2022 was 26.3%.
• Hospital pharmacies hold a 35% market share.
• Generic sildenafil starts from USD 8.5 or less per pill.
• The WHO estimates that between 30 and 70% of diabetic males have experienced ED over a lifetime.
• North America accounted for 51.7% of the total revenue for erectile dysfunction drugs in 2022.
• In September 2022, approximately half of American men between 40 and 70 years old were affected by ED.
• Retail pharmacies hold the largest market share in the end-user segment at 46%.

By Drug Type Analysis

The citrate Viagra (sildenafil citrate) segment held the dominant share of 58% in 2022

Based on drug type, the market for erectile dysfunction drugs is segmented into viagra (sildenafil citrate), cialis (tadalafil), stendra/spedra (avanafil), zydena (udenafil), levitra/staxyn (vardenafil), vitaros (alprostadil cream), and other drugs. Among these types, viagra (sildenafil citrate) holds a dominant share of 58% of the erectile dysfunction drugs market.

Viagra is distinguished from other PDE 5 (phosphodiesterase) inhibitors due to their long duration of action and lower side effect such as muscle pain and visual disorders. In addition, the increased effectiveness and performance of unknown molecule types and drug delivery methods like creams and pellets also boost the market growth.

Market growth is expected in the other segment as well. The increase in other drug sales is due to the availability of many ED medicines, such as helleva (iodenafil carbonate), mvix(mirodenafil), and other medications that can be used to treat adult patients who have erectile dysfunction. In addition, access to ED treatments is easy with the increasing acceptance of over-the-counter ED products.

By Distribution Channel Analysis

In 2022, retail pharmacies accounted for dominating the market with the largest revenue share

Based on distribution channels, the global erectile dysfunction market is divided into hospital pharmacies, retail pharmacies, and online pharmacies. Retail pharmacies hold a most significant market revenue share of 46% due to their easy access to medicine and the availability of generic ED drugs through retail pharmacies. The market share of hospital pharmacies was 35%.

Hospitals have seen a rise in revenue due to erectile dysfunction and other sexual-related disorders. Hospital pharmacies are mainly funded by developed countries, as patients prefer the prescribed medication for erectile dysfunction. The COVID-19 pandemic caused a decline in hospital pharmacy growth in 2020.

Online pharmacies are a crucial tool in the delivery of erectile dysfunction medications. The segment growth is aided by the ease of medication access and the reduced stigma surrounding sexual dysfunctions. Online portals are now available from pharmaceutical companies like Pfizer and Cipla. They offer ED medication via CiplaMed or Viagra websites.

This development increases the patient’s preference to choose from various drugs. Due to the COVID-19 pandemic, which increased online medicine purchases, online pharmacies saw a higher growth rate than retail and hospital pharmacies in 2020.

Key Market Segments

Based on Drug Type

• Viagra (sildenafil citrate)
• Cialis (Tadalafil)
• Stendra/Spedra (avanafil)
• Zydena (udenafil)
• Levitra/Staxyn (vardenafil)
• Vitaros (Alprostadil Cream)
• Other Drugs

Based on Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Drivers

Adoption of poor lifestyle choices to boost the market growth

Diabetes, obesity, and heart disease are all rising due to a poor lifestyle. This leads to issues like ED as people get older. Many young people in emerging countries have a stressful lifestyle, which leads to increased drinking, smoking, fast food, or ready-to-eat food consumption.

These factors can lead to a decline in overall health and fitness, which increases the likelihood of developing erectile dysfunction and needing treatment. As a result, the demand for ED drugs rises and boosts the growth of the market

The rising geriatric population, increasing knowledge of individuals, and brand loyalty support the market growth

The global erectile dysfunction drugs market will likely be driven by an increasing number of aged individuals, among whom the ED has become the most common health problem. Smooth progress in the erectile dysfunction market is due to patients’ increasing knowledge of the condition and the increase in education levels worldwide. The rise in lifestyle disorders also supports market growth. Market value is further enhanced by strong brand loyalty and the increasing popularity of brands like levitra/staxyn/cialis, viagra, and cialis.

Restraints

Market growth is hindered by low awareness and side effects of the ED drugs

Erectile dysfunction drugs are most popularly sold in emerging and developed economies. However, their sales in low- and mid-income countries are more downward. This is due to a lack of knowledge, lower buying power, and a decreased willingness to accept these medications daily. The slow growth of this market is also due to side effects such as nausea, headaches, dizziness, and diarrhea.

Opportunity

Increasing pharmaceutical production in emerging countries to offer better market expansion opportunities.

Over the past few years, emerging and established brands in the pharmaceutical industry have increased their investments in emerging countries such as India, China, and the Middle East & Africa. This has resulted in significant reductions in medicine prices and increased drug supply and distribution in these countries. In addition, advertising investments are likely to play an essential role in the growth of the global market for erectile dysfunction drugs.

Trends

Rising use of generic drugs and ED caused by diabetic conditions

Generic sildenafil can be purchased at a lower cost than viagra, depending on the dose. Viagra typically costs about US$ 70 to 75 per pill, while generic sildenafil starts from US$ 8.5 or lower. This availability of affordable medication may result in higher prescription rates and increased market expansion.

According to the WHO, about 30 to 70% of male diabetic patients have experienced an ED for a lifetime or a long time. Diabetic conditions can also ruin sexual life at a very early age. Hence diabetic individuals need an ED drug to overcome this condition, which will likely propel the market growth.

Regional Analysis

North America dominated the global market for ED drugs with the largest revenue share

Based on region, the global erectile dysfunction drugs market is classified into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America was the dominant market for erectile dysfunction drugs, accounting for 51.7% of the total revenue in 2021.

This is due to its high prevalence, robust healthcare infrastructure, and approval of new treatments. According to MSD Manuals’ September 2022 publication, approximately 50% of American men aged 40-70 years are affected by ED. This percentage rises with age.

The Asia Pacific market for erectile dysfunction drugs is expected to increase during the forecast period. The entry of new products into the region has contributed to the region’s growth.

Key Regions

• North America
  • The US
  • Canada
  • Mexico
• Western Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Portugal
  • Ireland
  • Austria
  • Switzerland
  • Benelux
  • Nordic
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • The Czech Republic
  • Greece
  • Rest of Eastern Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Australia & New Zealand
  • Indonesia
  • Malaysia
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC
• Latin America
  • Brazil
  • Colombia
  • Chile
  • Argentina
  • Costa Rica
  • Rest of Latin America
• Middle East & Africa
  • Algeria
  • Egypt
  • Israel
  • Kuwait
  • Nigeria
  • Saudi Arabia
  • South Africa
  • Turkey
  • United Arab Emirates
  • Rest of MEA

Key Players Analysis

Due to the availability of generic versions, the ED drugs market will experience steady growth. Global players offer generic versions of branded drugs to treat ED. Because of the availability of generic medicines at low prices and OTC topical formulations, the market is highly competitive.

Moreover, the key market players are implementing numerous growth strategies to expand their portfolios. As a result, they are involved in collaborations, partnerships, mergers & acquisitions, and new product launches. This in turn forms the competitive landscape among the market players.

Market Key Players

• GlaxoSmithKline plc,
• Pfizer Inc.
• Eli Lilly and Company
• Bayer AG
• Lupin Limited
• Sun Pharmaceutical Industries, Ltd.
• Teva Pharmaceutical Industries, Ltd.
• Sanofi S.A.
• VIVUS LLC.
• Petros Pharmaceuticals, Inc.
• Auxilium Pharmaceuticals, Inc.
• Dong-A Pharmaceutical Co., Ltd.
• Other Key Players

Recent Developments

• In September 2021, iX Biopharma signed an agreement with CRPCG to license, supply and distribute Wafesil (a sublingual sildenafil wafer) to treat male erectile dysfunction in China through its wholly-owned subsidiary.

• In September 2021, Almus Erectile Dysfunction Relief 50mg Film Coated Almus launched tablets in the pharmaceutical market of the UK.

Report Scope